Vor Biopharma Analyst Price Targets - Benzinga

Vor Biopharma Inc

VORNASDAQ

Trade with Public

Trade with Public

$19.68

-1.23-5.88%

Últ. Act.: Nov 2, 8:18 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Vor Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vor Biopharma (VOR).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

11Buy

2Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$62Upside to Avg. PT+214.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	William Blair	Myles Minter	Initiate	Outperform	—
Aug 12, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$18→$27
May 18, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$31
May 14, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$15→$18
Apr 15, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$32→$31
Mar 31, 2026	Wedbush	Martin Fan	PT Raise	Neutral	$9→$15
Mar 30, 2026	Jefferies	Farzin Haque	Initiate	Buy	$50
Mar 19, 2026	Wells Fargo	Sadia Rahman	Initiate	Overweight	$30
Jan 9, 2026	Citigroup	Geoff Meacham	Initiate	Buy	$50
Dec 19, 2025	JP Morgan	Anupam Rama	PT Cut	Overweight	$43→$40
Dec 17, 2025	TD Cowen	Yaron Werber	Initiate	Buy	—
Dec 9, 2025	JP Morgan	Anupam Rama	Initiate	Overweight	$43
Nov 25, 2025	Wedbush	Martin Fan	Assumes	Neutral	$9
Nov 14, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Cut	Buy	$55→$32
Oct 29, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$3→$52
Oct 15, 2025	Baird	Jack Allen	Upgrade	Neutral→Outperform	$20→$64
Aug 14, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$60
Jun 30, 2025	HC Wainwright & Co.	Swayampakula Ramakanth	Upgrade	Neutral→Buy	$60
Jun 27, 2025	Baird	Jack Allen	PT Raise	Neutral	$5→$20
Jun 26, 2025	Wedbush	David Nierengarten	Maintained	Neutral	$8

Analyst Ratings News

PRO
William Blair Initiates Coverage On Vor Biopharma with Outperform Rating

William Blair analyst Myles Minter initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Outperform rating.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with a Buy and maintains $31 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $15 to $18.

Benzinga Newsdesk

Microsoft To $500? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and upgrades/downgrades on our analyst ratings page.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $31

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vor Biopharma (NASDAQ:VOR) with a Buy and lowers the price target from $32 to $31.

Benzinga Newsdesk